Submission of data to BloodPac is easier to do for tissue not for liquid biopsy; there is lack of harmonization across many of these databanks Reimbursement: is a barrier to access for liquid biopsy Illumina: challenge finding clinical utility for payers; FDA approval is not as hard; show im...
Piqray is the first new drug application (NDA) for a new molecular entity approved under the Real-Time Oncology Review (RTOR) pilot program, which permits the FDA to begin analyzing key efficacy and safety datasets prior to the official submission of an application, allowing the review team to...
Submission of data to BloodPac is easier to do for tissue not for liquid biopsy; there is lack of harmonization across many of these databanks Reimbursement: is a barrier to access for liquid biopsy Illumina: challenge finding clinical utility for payers; FDA approval is not as hard; show im...